Vanda Pharmaceuticals Inc. VM4.F Stock
Vanda Pharmaceuticals Inc. Price Chart
Vanda Pharmaceuticals Inc. VM4.F Financial and Trading Overview
Vanda Pharmaceuticals Inc. stock price | 5.55 EUR |
Previous Close | 5.75 EUR |
Open | 5.75 EUR |
Bid | 5.75 EUR x 30000 |
Ask | 5.85 EUR x 30000 |
Day's Range | 5.75 - 5.75 EUR |
52 Week Range | 5.5 - 11.5 EUR |
Volume | 75 EUR |
Avg. Volume | 10 EUR |
Market Cap | 330.3M EUR |
Beta (5Y Monthly) | 0.679577 |
PE Ratio (TTM) | 22.115385 |
EPS (TTM) | -0.08 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 24 EUR |
VM4.F Valuation Measures
Enterprise Value | -146098160 EUR |
Trailing P/E | 22.115385 |
Forward P/E | 9.583333 |
PEG Ratio (5 yr expected) | 0.41 |
Price/Sales (ttm) | 1.2867901 |
Price/Book (mrq) | 0.61648977 |
Enterprise Value/Revenue | -0.569 |
Enterprise Value/EBITDA | -7.811 |
Trading Information
Vanda Pharmaceuticals Inc. Stock Price History
Beta (5Y Monthly) | 0.679577 |
52-Week Change | -32.20% |
S&P500 52-Week Change | 20.43% |
52 Week High | 11.5 EUR |
52 Week Low | 5.5 EUR |
50-Day Moving Average | 5.86 EUR |
200-Day Moving Average | 7.78 EUR |
VM4.F Share Statistics
Avg. Volume (3 month) | 10 EUR |
Avg. Daily Volume (10-Days) | 7 EUR |
Shares Outstanding | 57.44M |
Float | 52.84M |
Short Ratio | N/A |
% Held by Insiders | 3.96% |
% Held by Institutions | 100.15% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 6.21% |
Operating Margin (ttm) | 6.23% |
Gross Margin | 90.88% |
EBITDA Margin | 7.28% |
Management Effectiveness
Return on Assets (ttm) | 1.60% |
Return on Equity (ttm) | 3.07% |
Income Statement
Revenue (ttm) | 256.69M EUR |
Revenue Per Share (ttm) | 4.53 EUR |
Quarterly Revenue Growth (yoy) | 3.79% |
Gross Profit (ttm) | 230.1M EUR |
EBITDA | 18.7M EUR |
Net Income Avi to Common (ttm) | 15.96M EUR |
Diluted EPS (ttm) | 0.26 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 501.5M EUR |
Total Cash Per Share (mrq) | 8.73 EUR |
Total Debt (mrq) | 10.73M EUR |
Total Debt/Equity (mrq) | 2 EUR |
Current Ratio (mrq) | 5.69 |
Book Value Per Share (mrq) | 9.327 |
Cash Flow Statement
Operating Cash Flow (ttm) | 59.74M EUR |
Levered Free Cash Flow (ttm) | 55.78M EUR |
Profile of Vanda Pharmaceuticals Inc.
Country | Germany |
State | DC |
City | Washington |
Address | 2200 Pennsylvania Avenue NW |
ZIP | 20037 |
Phone | 202 734 3400 |
Website | https://www.vandapharma.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 290 |
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Q&A For Vanda Pharmaceuticals Inc. Stock
What is a current VM4.F stock price?
Vanda Pharmaceuticals Inc. VM4.F stock price today per share is 5.55 EUR.
How to purchase Vanda Pharmaceuticals Inc. stock?
You can buy VM4.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Vanda Pharmaceuticals Inc.?
The stock symbol or ticker of Vanda Pharmaceuticals Inc. is VM4.F.
Which industry does the Vanda Pharmaceuticals Inc. company belong to?
The Vanda Pharmaceuticals Inc. industry is Biotechnology.
How many shares does Vanda Pharmaceuticals Inc. have in circulation?
The max supply of Vanda Pharmaceuticals Inc. shares is 59.85M.
What is Vanda Pharmaceuticals Inc. Price to Earnings Ratio (PE Ratio)?
Vanda Pharmaceuticals Inc. PE Ratio is now.
What was Vanda Pharmaceuticals Inc. earnings per share over the trailing 12 months (TTM)?
Vanda Pharmaceuticals Inc. EPS is -0.08 EUR over the trailing 12 months.
Which sector does the Vanda Pharmaceuticals Inc. company belong to?
The Vanda Pharmaceuticals Inc. sector is Healthcare.